Header Logo

Connection

MICHAEL JAMES OVERMAN to Retrospective Studies

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Retrospective Studies.
MICHAEL JAMES OVERMAN
Connection Strength
0.907
Retrospective Studies
  1. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
    View in: PubMed
    Score: 0.045
  2. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open. 2021 06; 6(3):100132.
    View in: PubMed
    Score: 0.038
  3. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open. 2020 11; 5(6):e000960.
    View in: PubMed
    Score: 0.037
  4. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol. 2019 03 01; 5(3):402-405.
    View in: PubMed
    Score: 0.033
  5. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. 2019 06; 24(6):e384-e386.
    View in: PubMed
    Score: 0.033
  6. Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. Oncologist. 2019 04; 24(4):483-490.
    View in: PubMed
    Score: 0.032
  7. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst. 2018 08 01; 110(8):888-894.
    View in: PubMed
    Score: 0.032
  8. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331.
    View in: PubMed
    Score: 0.029
  9. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016 Feb; 5(2):239-47.
    View in: PubMed
    Score: 0.026
  10. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer. 2016 Jan 15; 122(2):213-21.
    View in: PubMed
    Score: 0.026
  11. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8.
    View in: PubMed
    Score: 0.023
  12. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.
    View in: PubMed
    Score: 0.023
  13. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
    View in: PubMed
    Score: 0.022
  14. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658.
    View in: PubMed
    Score: 0.019
  15. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol. 2010 May; 49(4):474-9.
    View in: PubMed
    Score: 0.018
  16. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
    View in: PubMed
    Score: 0.018
  17. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45.
    View in: PubMed
    Score: 0.016
  18. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336.
    View in: PubMed
    Score: 0.012
  19. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260.
    View in: PubMed
    Score: 0.012
  20. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist. 2023 Dec 11; 28(12):e1303-e1305.
    View in: PubMed
    Score: 0.011
  21. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517.
    View in: PubMed
    Score: 0.011
  22. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol. 2024 Jan; 31(1):614-621.
    View in: PubMed
    Score: 0.011
  23. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490.
    View in: PubMed
    Score: 0.011
  24. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw. 2022 08; 20(8):887-897.e3.
    View in: PubMed
    Score: 0.010
  25. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.010
  26. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
    View in: PubMed
    Score: 0.010
  27. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.010
  28. Underreporting of race/ethnicity in COVID-19 research. Int J Infect Dis. 2021 Jul; 108:419-421.
    View in: PubMed
    Score: 0.010
  29. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.010
  30. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.010
  31. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
    View in: PubMed
    Score: 0.009
  32. Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. Abdom Radiol (NY). 2020 09; 45(9):2886-2894.
    View in: PubMed
    Score: 0.009
  33. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270.
    View in: PubMed
    Score: 0.009
  34. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199.
    View in: PubMed
    Score: 0.009
  35. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
    View in: PubMed
    Score: 0.009
  36. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.009
  37. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.009
  38. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.009
  39. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer. 2019 Oct 17; 19(1):965.
    View in: PubMed
    Score: 0.009
  40. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.009
  41. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 11; 24(11):1453-1461.
    View in: PubMed
    Score: 0.008
  42. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
    View in: PubMed
    Score: 0.008
  43. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249.
    View in: PubMed
    Score: 0.008
  44. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417.
    View in: PubMed
    Score: 0.008
  45. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.008
  46. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.008
  47. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102.
    View in: PubMed
    Score: 0.008
  48. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13):3954-3963.
    View in: PubMed
    Score: 0.007
  49. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.007
  50. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.007
  51. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.
    View in: PubMed
    Score: 0.007
  52. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.007
  53. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193.
    View in: PubMed
    Score: 0.007
  54. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017 02; 161(2):332-340.
    View in: PubMed
    Score: 0.007
  55. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.007
  56. Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Ann Surg Oncol. 2016 09; 23(9):2914-9.
    View in: PubMed
    Score: 0.007
  57. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7.
    View in: PubMed
    Score: 0.007
  58. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.006
  59. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015 Mar 17; 112(6):1088-97.
    View in: PubMed
    Score: 0.006
  60. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015 Apr; 26(4):731-736.
    View in: PubMed
    Score: 0.006
  61. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
    View in: PubMed
    Score: 0.006
  62. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8.
    View in: PubMed
    Score: 0.006
  63. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med. 2013 Nov; 137(11):1619-26.
    View in: PubMed
    Score: 0.006
  64. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
    View in: PubMed
    Score: 0.005
  65. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer. 2012 Apr; 48(6):820-6.
    View in: PubMed
    Score: 0.005
  66. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4.
    View in: PubMed
    Score: 0.005
  67. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011 Jul 01; 17(13):4531-40.
    View in: PubMed
    Score: 0.005
  68. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer. 2011 Sep; 10(3):178-82.
    View in: PubMed
    Score: 0.005
  69. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92.
    View in: PubMed
    Score: 0.005
  70. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.
    View in: PubMed
    Score: 0.005
  71. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22.
    View in: PubMed
    Score: 0.004
  72. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
    View in: PubMed
    Score: 0.004
  73. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.